Literature DB >> 3654911

Human retroocular fibroblasts in vitro: a model for the study of Graves' ophthalmopathy.

R S Bahn1, C A Gorman, G E Woloschak, C S David, P M Johnson, C M Johnson.   

Abstract

Orbital connective tissue and extraocular muscles are histologically abnormal in patients with Graves' ophthalmopathy (GO). Although extraocular muscles have been extensively studied as a target for autoimmune attack in the disease, no system has been available to study retroocular fibroblasts in GO. We developed a technique to isolate fibroblasts from minced explants of connective tissue removed in the course of transantral orbital decompression surgery for GO. Postmortem specimens from individuals without evidence of thyroid disease were obtained from the same anatomical site. Confluent cells could be passaged at least 10 times with stable morphology and frozen with greater than 75% viability. An enzyme-linked immunosorbent assay was used to study the in vitro binding of serum immunoglobulin G (IgG) to these cells. We found no difference in the degree of specific binding between GO cells and cells from normal individuals. However, there was significantly greater binding of IgG from GO sera than of that from normal serum to retroocular GO fibroblasts. These results suggest that serum IgG autoantibodies against normal retroocular fibroblasts are present in some GO patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3654911     DOI: 10.1210/jcem-65-4-665

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Autoimmunity in Graves' ophthalmopathy: a review.

Authors:  A P Weetman
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

2.  Extraocular muscle changes in experimental orbital venous stasis: some similarities to Graves' orbitopathy.

Authors:  E Saber; J McDonnell; K M Zimmermann; J E Yugar; S E Feldon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-05       Impact factor: 3.117

3.  High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy.

Authors:  P E Macchia; M Bagattini; G Lupoli; M Vitale; G Vitale; G Fenzi
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

Review 4.  Graves' ophthalmopathy: what is the evidence for extraocular muscle specific autoantibodies.

Authors:  R van der Gaag; R Vernimmen; N Fiebelkorn; M C van Dierendonck; A Kijlstra
Journal:  Int Ophthalmol       Date:  1990-01       Impact factor: 2.031

5.  A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.

Authors:  Seema Kumar; Reagan Schiefer; Michael J Coenen; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

Review 6.  Graves' ophthalmopathy.

Authors:  W E Barrie
Journal:  West J Med       Date:  1993-06

7.  Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.

Authors:  Seema Kumar; Michael Coenen; Seethalakshmi Iyer; Rebecca S Bahn
Journal:  Thyroid       Date:  2015-08-19       Impact factor: 6.568

Review 8.  Potential Roles of CD34+ Fibrocytes Masquerading as Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

9.  Demonstration of thyrotropin binding sites in orbital connective tissue: possible role in the pathogenesis of thyroid-associated ophthalmopathy.

Authors:  P Perros; P Kendall-Taylor
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

10.  Use of eye muscle antibody measurements to monitor response to plasmapheresis in patients with thyroid-associated ophthalmopathy.

Authors:  C Atabay; M Schrooyen; Z G Zhang; M Salvi; D Glinoer; J R Wall
Journal:  J Endocrinol Invest       Date:  1993-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.